ReviewClinical journal of the American Society of Nephrology : CJASN2026
Kidney Denervation: Latest Breakthroughs and Insights.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney denervation has emerged as an interventional treatment for the ever-increasing prevalence of uncontrolled hypertension that recently garnered Unites States Food and Drug Administration approval. Kidney denervation is a minimally invasive catheter-based procedure that ablates the sympathetic nerves around the kidney arteries using a variety of modalities. Clinical trial data have generally demonstrated that kidney denervation is a safe procedure, but efficacy data are mixed. In addition, important populations were excluded from these trials, including patients with advanced CKD and kidney transplants. Currently, it is still unclear which patients with hypertension will have an appropriate therapeutic effect after undergoing kidney denervation, and there is no available biomarker to assist in predicting a patient's blood pressure response after kidney denervation. When considering when to offer kidney denervation, patients should ideally be evaluated by a multidisciplinary team with the proper expertise to evaluate the appropriateness of the referral and discuss the risks and benefits to allow for shared decision-making. Ongoing and future studies will help to address current unanswered questions that remain about longer-term safety and efficacy of kidney denervation, particularly in populations poorly represented by current trials. Kidney denervation can be an important therapy that can be used to complement antihypertensive medications and lifestyle changes to improve hypertension control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.